Literature DB >> 6207267

Pain as a symptom in depressive disorders and its relationship to platelet monoamine oxidase activity.

L von Knorring, C Perris, L Oreland, M Eisemann, U Eriksson, H Perris.   

Abstract

144 depressed in-patients were rated by means of the Comprehensive Psychopathological Rating Scale (CPRS) and platelet monoamine oxidase (MAO) was determined. 49 per cent of the patients were found to have pain as a symptom, and 21 per cent were found to have more severe pain. The patients with more severe pain were found to have lower platelet MAO activity than the patients without pain or with slight pain. As platelet MAO activity may reflect the turn-over in the serotinergic systems in CNS it is hypothesized that patients with depressive disorders with pain as a symptom may have more pronounced disturbances in the serotinergic systems than patients without pain as a symptom.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207267     DOI: 10.1007/bf01254760

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  26 in total

1.  Non-psychotic depressive disorders: a ten year follow-up.

Authors:  G d'Elia; L von Knorring; C Perris
Journal:  Acta Psychiatr Scand Suppl       Date:  1974

2.  Cerebral monoamines and depression. An investigation with the Probenecid technique.

Authors:  H M van Praag; J Korf; D Schut
Journal:  Arch Gen Psychiatry       Date:  1973-06

3.  A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. II. Childhood environment and precipitating factors.

Authors:  C Perris
Journal:  Acta Psychiatr Scand Suppl       Date:  1966

4.  The relationship of chronic pain to depression, marital adjustment, and family dynamics.

Authors:  S N Mohamed; G M Weisz; E M Waring
Journal:  Pain       Date:  1978-10       Impact factor: 6.961

5.  Platelet monoamine oxidase activity in mental disorders: 2. Affective psychoses and suicidal behavior.

Authors:  C G Gottfries; L von Knorring; L Oreland
Journal:  Prog Neuropsychopharmacol       Date:  1980

6.  Interprofessional communicability and reliability of the Comprehensive Psychopathological Rating Scale (CPRS) as assessed by video-taped interviews.

Authors:  C Perris; U Ericsson; L Jacobsson; H Lindström; H Perris
Journal:  Acta Psychiatr Scand       Date:  1979-08       Impact factor: 6.392

7.  5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor?

Authors:  M Asberg; L Träskman; P Thorén
Journal:  Arch Gen Psychiatry       Date:  1976-10

8.  Chronic pain as a variant of depressive disease: the pain-prone disorder.

Authors:  D Blumer; M Heilbronn
Journal:  J Nerv Ment Dis       Date:  1982-07       Impact factor: 2.254

9.  The genetics of depression. A family study of unipolar and neurotic-reactive depressed patients.

Authors:  C Perris; H Perris; U Ericsson; L von Knorring
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

10.  Suicide attempts, platelet monoamine oxidase and the average evoked response.

Authors:  M S Buchsbaum; R J Haier; D L Murphy
Journal:  Acta Psychiatr Scand       Date:  1977-07       Impact factor: 6.392

View more
  4 in total

1.  Platelet MAO in patients with idiopathic pain disorders.

Authors:  B G Almay; L von Knorring; L Oreland
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

2.  Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin.

Authors:  L von Knorring; B G Almay; J Häggendal; F Johansson; L Oreland; L Wetterberg
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

Review 3.  Idiopathic pain and depression.

Authors:  L von Knorring; L Ekselius
Journal:  Qual Life Res       Date:  1994-12       Impact factor: 4.147

Review 4.  Psychiatric disorders and pain: The recurrence of a comorbidity.

Authors:  Gentian Vyshka
Journal:  World J Clin Cases       Date:  2022-09-26       Impact factor: 1.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.